Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 149

1.

Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin.

MacIsaac J, Siddiqi R, Jamula E, Li N, Baker S, Webert KE, Evanovitch D, Heddle NM, Arnold DM.

Transfusion. 2018 Sep 23. doi: 10.1111/trf.14841. [Epub ahead of print] Review.

PMID:
30244480
2.

Rituximab Treatment in Myasthaenia Gravis: Report of two paediatric cases.

Koul R, Al-Futaisi A, Abdelrahim R, Mani R, Abdwani R, Al-Asmi A.

Sultan Qaboos Univ Med J. 2018 May;18(2):e223-e227. doi: 10.18295/squmj.2018.18.02.018. Epub 2018 Sep 9.

3.

Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.

Crusz SM, Radunovic A, Shepherd S, Shah S, Newey V, Phillips M, Lim L, Powles T, Szlosarek PW, Shamash J, Rashid S.

Eur J Cancer. 2018 Oct;102:49-51. doi: 10.1016/j.ejca.2018.07.125. Epub 2018 Aug 20. No abstract available.

PMID:
30138772
4.

New Pathways and Therapeutic Targets in Autoimmune Myasthenia Gravis.

Behin A, Le Panse R.

J Neuromuscul Dis. 2018;5(3):265-277. doi: 10.3233/JND-170294.

5.

Concurrent inflammatory myopathy and myasthenia gravis with or without thymic pathology: A case series and literature review.

Huang K, Shojania K, Chapman K, Amiri N, Dehghan N, Mezei M.

Semin Arthritis Rheum. 2018 Jun 26. pii: S0049-0172(18)30108-2. doi: 10.1016/j.semarthrit.2018.05.004. [Epub ahead of print]

PMID:
29958689
6.

Advances in autoimmune myasthenia gravis management.

Wang S, Breskovska I, Gandhy S, Punga AR, Guptill JT, Kaminski HJ.

Expert Rev Neurother. 2018 Jul;18(7):573-588. doi: 10.1080/14737175.2018.1491310. Epub 2018 Jul 4.

PMID:
29932785
7.

The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis.

Cortés-Vicente E, Rojas-Garcia R, Díaz-Manera J, Querol L, Casasnovas C, Guerrero-Sola A, Muñoz-Blanco JL, Bárcena-Llona JE, Márquez-Infante C, Pardo J, Martínez-Fernández EM, Usón M, Oliva-Nacarino P, Sevilla T, Illa I.

Ann Clin Transl Neurol. 2018 Apr 14;5(6):710-716. doi: 10.1002/acn3.564. eCollection 2018 Jun.

8.

Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis.

Landon-Cardinal O, Friedman D, Guiguet M, Laforêt P, Heming N, Salort-Campana E, Jouen F, Allenbach Y, Boyer O, Chatenoud L, Eymard B, Sharshar T, Benveniste O.

J Neuromuscul Dis. 2018;5(2):241-249. doi: 10.3233/JND-180300.

PMID:
29865089
9.

[Myasthenic Crisis].

Stetefeld HR, Schroeter M.

Fortschr Neurol Psychiatr. 2018 May;86(5):301-307. doi: 10.1055/a-0599-0811. Epub 2018 May 29. German.

PMID:
29843179
10.

Serological Immunoglobulin-Free Light Chain Profile in Myasthenia Gravis Patients.

Basile U, Marino M, Napodano C, Pocino K, Alboini PE, Gulli F, Evoli A, Provenzano C, Bartoccioni E.

J Immunol Res. 2018 Mar 25;2018:9646209. doi: 10.1155/2018/9646209. eCollection 2018.

11.

Rituximab in refractory myasthenia gravis: Extended prospective study results.

Beecher G, Anderson D, Siddiqi ZA.

Muscle Nerve. 2018 Sep;58(3):452-455. doi: 10.1002/mus.26156. Epub 2018 Aug 23.

PMID:
29742795
12.

Myasthenia gravis with muscle-specific tyrosine kinase antibodies: A narrative review.

Morren J, Li Y.

Muscle Nerve. 2018 Sep;58(3):344-358. doi: 10.1002/mus.26107. Epub 2018 Mar 25. Review.

PMID:
29461627
13.

When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies.

Mantegazza R, Antozzi C.

Ther Adv Neurol Disord. 2018 Jan 18;11:1756285617749134. doi: 10.1177/1756285617749134. eCollection 2018. Review. Erratum in: Ther Adv Neurol Disord. 2018 Mar 21;11:1756286418765591.

14.

Rituximab in myasthenia gravis: a "to be or not to be" inhibitor of T cell function.

Marino M, Bartoccioni E, Alboini PE, Evoli A.

Ann N Y Acad Sci. 2018 Feb;1413(1):41-48. doi: 10.1111/nyas.13562. Epub 2018 Jan 25. Review.

PMID:
29369382
15.

Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases.

Memon AB, Javed A, Caon C, Srivastawa S, Bao F, Bernitsas E, Chorostecki J, Tselis A, Seraji-Bozorgzad N, Khan O.

PLoS One. 2018 Jan 8;13(1):e0190425. doi: 10.1371/journal.pone.0190425. eCollection 2018.

16.

Myastenia and small doses of ionizing radiation: experience of successful use of rituximab for treatment of an irradiated with myasthenia gravis.

Kravchenko VI, Chumak AA, Loganovsky KM, Diagil IS, Kuzmenko VF.

Probl Radiac Med Radiobiol. 2017 Dec;22:395-405. English, Ukrainian.

PMID:
29286523
17.

Myasthenia gravis with antibodies to MuSK: an update.

Evoli A, Alboini PE, Damato V, Iorio R, Provenzano C, Bartoccioni E, Marino M.

Ann N Y Acad Sci. 2018 Jan;1412(1):82-89. doi: 10.1111/nyas.13518. Epub 2017 Dec 21. Review.

PMID:
29266255
18.

Refractory Myasthenia Gravis Treated Successfully with Rituximab: A Case Report.

Rahul LY, Dakua T, Mukherjee A.

Ann Indian Acad Neurol. 2017 Oct-Dec;20(4):436-437. doi: 10.4103/aian.AIAN_233_17. No abstract available.

19.

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.

Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group.

Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Erratum in: Lancet Neurol. 2017 Dec;16(12 ):954.

PMID:
29066163
20.

[Effectiveness and safety of rituximab for children with autoimmune diseases of the nervous system].

Fu Z, Bao XH, Wu Y, Zhou J, Zhang YH, Zhang Y, Ji TY, Chen Y.

Zhonghua Er Ke Za Zhi. 2017 Sep 2;55(9):689-694. doi: 10.3760/cma.j.issn.0578-1310.2017.09.013. Chinese.

PMID:
28881516

Supplemental Content

Loading ...
Support Center